Seasonal affective disorder (SAD) is a mood disorder subset in which people who have normal mental health throughout most of the year exhibit depressive symptoms at the same time each year, most commonly in the winter. Common symptoms include sleeping too much, having little to no energy, and overeating. The condition in the summer can include heightened anxiety.

According to this study, over the next five years the Seasonal Affective Disorder Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Seasonal Affective Disorder Therapeutics business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Seasonal Affective Disorder Therapeutics market by product type, application, key companies and key regions.

This study considers the Seasonal Affective Disorder Therapeutics value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Light Therapy (Phototherapy)
Medication
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospitals
Clinics
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Allergan
Pfizer
Roche
Eli Lily
GlaxoSmithKline
Teva Pharmaceuticals
Bausch Health Companies
Mylan
Sanofi
Novartis
Johnson & Johnson
Koninklijke Philips
Beurer GmbH
Lucimed (Luminette)

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Seasonal Affective Disorder Therapeutics market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Seasonal Affective Disorder Therapeutics market by identifying its various subsegments.
Focuses on the key global Seasonal Affective Disorder Therapeutics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Seasonal Affective Disorder Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Seasonal Affective Disorder Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.